Multimodal Imaging Based on Pathological and Genomic Characteristics

NCT05196243 | Unknown

• 1 other identifier: Multi-imaging
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

Mitochondrial DNA mutations in normal gastric tissue, early gastric cancer and advanced gastric cancer were identified by single cell sequencing, and the origin of gastric stem cells was traced and new molecular markers were found. At the same time, organize industry-university-research-medical inspection joint research, aiming at the advanced layout of new structural and functional imaging technologies, combined with some new imaging technologies, such as holography, fluorescence, etc., to explore and develop a new composite endoscopic imaging technology that is advanced, original and suitable for China's national conditions, in order to develop a prototype of multimodal structural and functional imaging digestive endoscope without contrast agent.

Conditions

Mitochondrial DNA Mutation; Endoscopy

Keywords

Mitochondrial DNA Mutation; Single cell sequencing; Molecular pathology; multimodal imaging; holography

Outcome Measures

Primary Outcomes (2)

• Single cell sequencing and identification of mitochondrial DNA variation in gastrointestinal lesions

  Single cell sequencing and identification of mitochondrial DNA mutations in gastrointestinal lesions were carried out to trace the clonal origin of cells and look for molecular markers

  1 month

• To explore the multimodal imaging technique for the diagnosis of gastrointestinal mucosal lesions

  The tissue characteristics are analyzed by the full spectrum imaging device, the location, distribution and aggregation of key molecules on the cell membrane are observed by the high resolution imaging device, the imaging probe with high labeling efficiency and biosafety is developed, and the clinical application is discussed. in order to realize the information fusion of structural and functional imaging in the process of gastrointestinal tumor evolution and diagnosis and treatment.

  1 month

Study Arms (2)

Study Group

Study on the genomic and molecular pathological characteristics of gastrointestinal mucosal lesions

Other: Patients diagnosed as gastrointestinal mucosal lesions

Control Group

Study on the genomic and molecular pathological characteristics of normal gastrointestinal mucosa

Interventions

Patients diagnosed as gastrointestinal mucosal lesions OTHER

Patients diagnosed as gastritis, gastric cancer, intestinal polyps and colorectal cancer

Study Group

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

People diagnosed or suspected of one of the following common digestive mucosal diseases: gastritis, gastric cancer, colorectal polyps, colorectal cancer

You may qualify if:

• Diagnosis or suspected diagnosis of one of the following common digestive mucosal diseases: gastritis, gastric cancer, colorectal polyps, bowel cancer
• Written informed consent

You may not qualify if:

• Patients with cardiovascular and cerebrovascular diseases, or patients with severe impairment of liver, kidney and hematopoietic system
• Mental patients
• Hemorrhagic diseases
• Platelet count \< 50 × 10 \^ 9 / L
• Allergic constitution
• unable to tolerate or cooperate with endoscopy
• Patients with serious complications, such as intestinal obstruction, intestinal perforation, toxic colonic dilatation, colorectal cancer, etc.
• Pregnant or lactating women

Sponsors & Collaborators

• Affiliated Hospital to Academy of Military Medical Sciences: lead

Study Sites (1)

The First Medical Center of Chinese PLA General Hospital

Beijing, Beijing Municipality, 100853, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Mucosal tissues or cells of gastritis, gastric cancer, intestinal polyps and colorectal cancer obtained by endoscopic biopsy or resection

Study Officials

• Yan Liu, MD

  Beijing 302 Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Yan Liu, MD

CONTACT

+8613911798288; 13911798288@163.com

Liang Wu, MD

CONTACT

+8618110076598; wuliangdoc@163.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 5, 2022
• First Posted: January 19, 2022
• Study Start: March 21, 2022
• Primary Completion: June 1, 2022
• Study Completion: July 1, 2024
• Last Updated: April 1, 2022

Record last verified: 2022-03

Locations

CN (1)